Research progress on pathogenesis and potential therapeutic target of sarcopenia obesity
10.12092/j.issn.1009-2501.2023.03.013
- Author:
Yixun GUO
1
;
Yingda WEI
1
;
Yan ZHANG
1
;
Xiaoyin GUAN
2
;
Bo WANG
2
;
Yan ZHANG
2
;
Jianhua LIN
2
Author Information
1. Longhua Hospital, Shanghai University of Traditional Chinese Medicine
2. Shenzhen Pingle Orthopaedic Hospital
- Publication Type:Journal Article
- Keywords:
adiponectin;
FGF19;
hippo pathway;
sarcopenia obesity
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(3):341-346
- CountryChina
- Language:Chinese
-
Abstract:
Sarcopenia obesity (SO), a specific disease with co-occurrence of obesity and sarcopenia, is shown clinically as abnormal accumulation of fat, decreased mass and strength of muscle, and increased risk of incidence and mortality of other chronic diseases. Currently, there exist various definitions and diagnoses about SO in the various regions of the world. Its prevalence in populations elevates in an age-dependent manner. This article summarized the possible pathogenesis of SO from the view of chronic inflammation, oxidative stress, insulin resistance, and Hippo pathway, subsequently listed and analyzed potential pharmacological targets (fibroblast growth factor, CD44, adiponectin, etc) involved in treating SO, in order to provide new ideas for clinical diagnosis, treatment of SO patients and research and development of innovative drugs.
